Parthenolide (Sesquiterpene Lactone · Migraine Prevention · NF-κB Inhibitor · LSC Targeting)
| Compound | Parthenolide |
| Chemical class | Terpenoid — Sesquiterpene Lactone (Eudesmanolide; germacranolide) |
| CAS | 20554-84-1 |
| Primary source | Tanacetum parthenium (feverfew, aerial parts and leaves) |
| Key applications | Migraine prevention; NF-κB inhibition; anti-inflammatory; leukaemia stem cell targeting |
| Claim strength | High (migraine); Moderate (anti-inflammatory, anticancer preclinical) |
| Typical form | Feverfew extract standardised to 0.2–0.8% parthenolide; parthenolide isolate |
| Buy from Herbuno |
Feverfew Oil Soluble Extract - Tanacetum parthenium → Parthenolide 0.8% Powder (Feverfew Extract) | Standardized Tanacetum parthenium → |
Name origin: From Parthenium (an older genus name for feverfew; from Greek parthenos = virgin, as the plant was dedicated to Athena). Parthenolide is the primary sesquiterpene lactone of feverfew, constituting approximately 0.1–0.9% of dried leaf weight. Its germacranolide scaffold contains an α-methylene-γ-lactone moiety — the electrophilic group responsible for its ability to alkylate cysteine residues in target proteins, including NF-κB. Traditional use: Feverfew (Tanacetum parthenium) has been used in European folk medicine since antiquity for fever (Latin febrifugium = fever-chaser), headache, and arthritis. Its migration from traditional herb to evidence-based supplement candidate began in the 1970s when anecdotal reports of migraine prevention prompted clinical investigation. Research trajectory: Parthenolide has two distinct evidence streams: (1) migraine prevention — multiple RCTs with modest but consistent benefit; (2) NF-κB inhibition and preferential leukaemia stem cell (LSC) killing — a highly active preclinical anticancer research area since 2005 (Jordan et al., Nature Medicine). The LSC-targeting property positions parthenolide as one of the first natural products to preferentially target cancer stem cells over bulk tumour cells. Commercial source: Feverfew oil soluble extract and Parthenolide 0 is available from Herbuno.2% and 0.8% standardised powders.
Evidence for Parthenolide Applications
Migraine prevention — RCT evidence: At least five placebo-controlled RCTs and two Cochrane-reviewed meta-analyses support feverfew extract (standardised to parthenolide) for migraine frequency reduction. The mechanism involves inhibition of platelet aggregation (thromboxane release inhibition), reduction of prostaglandin synthesis via PLA2 inhibition, and serotonin release inhibition from platelets — addressing multiple migraine pathophysiology targets. Effect size: approximately 24% reduction in migraine frequency versus placebo across meta-analyses. Claim strength: High.
NF-κB inhibition — broad anti-inflammatory: Parthenolide alkylates the p65 subunit of NF-κB and inhibits IκB kinase (IKK), preventing NF-κB nuclear translocation. This potent NF-κB inhibition accounts for its anti-inflammatory activity across multiple models (arthritis, colitis, neuroinflammation). The α-methylene-γ-lactone moiety provides the electrophilic warhead for irreversible cysteine alkylation — a covalent mechanism unusual among botanical anti-inflammatories. Claim strength: Moderate.
Leukaemia stem cell targeting: The 2005 Jordan laboratory study (Nature Medicine) demonstrated that parthenolide preferentially kills acute myeloid leukaemia (AML) stem cells and progenitors while sparing normal haematopoietic stem cells — a pharmacological selectivity profile that conventional chemotherapy lacks. The mechanism involves ROS-generating NF-κB inhibition specific to LSC’s elevated oxidative stress baseline. Parthenolide analogues with improved bioavailability (DMAPT — dimethylaminoparthenolide) have entered Phase I trials. Claim strength: Moderate (compelling preclinical; Phase I ongoing).
Feverfew Oil Soluble Extract - Tanacetum parthenium →
Parthenolide 0.8% Powder (Feverfew Extract) | Standardized Tanacetum parthenium →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Migraine prevention: 100–300 mg/day feverfew extract standardised to 0.2–0.8% parthenolide (delivering 0.2–0.6 mg parthenolide/day). Most RCTs used dried leaf preparations; standardised extracts should be specified by parthenolide HPLC content. Minimum effective dose in RCTs: 0.2 mg parthenolide/day from 0.2% standardised extract at 100 mg. Anti-inflammatory applications: higher dose range 300–600 mg/day standardised extract. Parthenolide degrades rapidly in aqueous solution and on exposure to heat/light — specify fresh-standardised extract with CoA within 12 months of manufacture. Avoid prolonged storage above 25°C. Contraindication: pregnancy (traditional uterotonic activity); anticoagulant drug interaction (antiplatelet effects compound warfarin).
Frequently Asked Questions — Parthenolide
How does parthenolide compare to triptans for migraine?
Parthenolide/feverfew is a preventive agent, not an acute abortive treatment. Triptans (sumatriptan, rizatriptan) are 5-HT1B/D agonists that abort an active migraine within 30–120 minutes — they are not effective as preventives. Parthenolide taken daily reduces the frequency of migraines over weeks to months but does not abort an attack already in progress. The appropriate comparison is to other preventive therapies (propranolol, amitriptyline, topiramate) — against which feverfew shows modest but genuine preventive benefit with a far more favourable safety profile.
Why does parthenolide preferentially kill leukaemia stem cells?
Leukaemia stem cells (LSCs) have elevated basal NF-κB activity compared to normal haematopoietic stem cells — NF-κB is constitutively active in AML LSCs, maintaining their survival and self-renewal. Parthenolide’s NF-κB inhibition therefore hits LSCs harder than normal stem cells (which are not NF-κB-dependent). Simultaneously, LSCs have higher basal ROS levels than normal HSCs; parthenolide increases ROS further, selectively pushing LSCs past the apoptosis threshold. Normal HSCs, with lower NF-κB dependency and lower basal ROS, are relatively spared at the same dose.
What is DMAPT and why is it being developed instead of parthenolide?
DMAPT (dimethylaminoparthenolide) is a water-soluble, orally bioavailable parthenolide prodrug developed specifically because parthenolide’s poor water solubility and rapid degradation limit systemic exposure after oral dosing. DMAPT hydrolyses to parthenolide after absorption. It retains the LSC-targeting pharmacology with dramatically improved oral bioavailability. DMAPT (LC-1) has entered Phase I clinical trials for AML and chronic lymphocytic leukaemia. The clinical programme validates parthenolide as a genuine anticancer pharmacophore while recognising the need for pharmaceutical development to improve delivery.
Can parthenolide cause mouth ulcers?
Yes — this is the most commonly reported adverse effect of chewing fresh feverfew leaves (the traditional preparation). The α-methylene-γ-lactone group alkylates oral mucosal proteins at direct contact, causing aphthous ulcers in approximately 10–15% of users of fresh leaf preparations. Standardised dried leaf extract or encapsulated powder avoids direct oral mucosal contact and is associated with significantly lower ulcer incidence. Formulators should specify encapsulated or tablet formats rather than chewable preparations for parthenolide-containing products.
Related compounds: Artemisinin, Absinthin, Zerumbone, Boswellic Acid
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery